GAVIN GIST: Open Payments
NPI 1952574048 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$910 in 27 payments from 11 companies in 2025. Trend: 2023 $3,656 · 2024 $1,272 · 2025 $910
Food & beverage: $910
| Company | Payments | Amount |
|---|---|---|
| Edwards Lifesciences Corporation | 1 | $200 |
| AstraZeneca Pharmaceuticals LP | 7 | $190 |
| Merck Sharp & Dohme LLC | 6 | $123 |
| E.R. Squibb & Sons, L.L.C. | 1 | $98 |
| Alnylam Pharmaceuticals Inc. | 1 | $94 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $59 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| PFIZER INC. | 2 | $37 |
| Amgen Inc. | 2 | $36 |
| Esperion Therapeutics, Inc. | 1 | $21 |
Products named: WAINUA, VERQUVO, CAMZYOS, AMVUTTRA, LOKELMA, JARDIANCE, Kerendia, VYNDAQEL.
Industry payments across MS — which companies pay providers there.
